Monday, June 5, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Crimean Congo Countermeasures: Researchers Investigate CCHFV-RDRp

by Global Biodefense Staff
June 11, 2019
Crimean-Congo Hemorrhagic Fever

Crimean-Congo hemorrhagic fever viral particles (orange). Credit NIAID, modified.

Even though Crimean-Congo Hemorrhagic Fever virus (CCHFV) is a very old and well-recognized disease, little effort has been put to eradicate either the disease or its symptoms. Besides ribavirin, T-705 has proven historically reliable in reducing CCHF viremia and has been found to be the most efficacious drug from a cohort of similar agents when used against a variety of CCHFV strains.

Recently, a screen of candidate nucleoside analog compounds identified 2′-deoxy-2′-fluorocytidine with increased activity in CCHFV compared to ribavirin and T-705and showed antiviral activity against several unrelated Bunyaviruses. Additionally, two repurposed FDA molecules chloroquine and chlorpromazine showed direct activity against CCHFV. However, there are practically no marketed alternatives available so far.

In a study published last month in Nature, researchers investigate CCHFV-RdRp, a critical mechanisms in the virus life cycle, which involves replication/transcription of vRNA in the cytoplasm of infected cell and an important target against CCHFV.

Because of the unavailability of CCHFV-RdRp crystal structure in the protein database, an extensive approach to model CCHFV-RdRp was undertaken to further identify potential anti-CCHFV compounds using integrated computational methods. The in silico methods provide a direct and scientifically well-funded basis to guide in vitro methods for antiviral drug discovery.

The reported strategy is cost and time efficient, starting from an extensively refined homology model of CCHFV RdRp as a potential druggable target, followed by step-wise pharmacophore-based virtual screening and all-atom backbone molecular dynamics simulation of potential hits.

Read the full paper at Nature.

Tags: Crimean-CongoEditor PickSelect Agents

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy